共 171 条
[1]
van Genugten RE(2004)K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease Am J Kidney Dis 43 S1-290
[2]
Möller-Goede DL(2013)Extra-pancreatic effects of incretin-based therapies: potential benefit for cardiovascular-risk management in type 2 diabetes Diabetes Obes Metab 15 593-606
[3]
van Raalte DH(2010)Nonalcoholic fatty liver disease: an overlooked complication of diabetes mellitus Nat Rev Endocrinol 6 660-661
[4]
Diamant M(1994)Dyslipidemia in non-insulin-dependent diabetes mellitus Endocr Rev 15 263-274
[5]
Arrese M(2012)A review of gliptins in 2011 Expert Opin Pharmacother 13 81-99
[6]
Howard BV(2015)DPP-4 inhibitors: focus on safety Expert Opin Drug Saf 14 127-140
[7]
Howard WJ(2017)Teneligliptin in management of diabetic kidney disease: a review of place in therapy J Clin Diagn Res 11 OE05-OE09
[8]
Scheen AJ(2015)Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus Exp Pharmacol Physiol 42 999-1024
[9]
Tella SH(2012)Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients J Clin Med Res 4 309-313
[10]
Rendell MS(2017)Comparative Effect of Calcium Channel Blockers on Glomerular Function in Hypertensive Patients with Diabetes Mellitus Drugs R D 17 403-412